Engineering a New Era
for Neuroscience
We are an AI-native biotechnology company designing a new class of intelligent biologics to cross the blood-brain barrier and halt neurodegenerative disease.
The Barrier to a Cure
For decades, the blood-brain barrier (BBB) has stood as the single greatest obstacle to treating neurodegenerative diseases. This highly selective, protective membrane is essential for brain health, but it also blocks more than 98% of potential large-molecule drugs from reaching their intended targets.
As a result, millions of patients with Parkinson's, Alzheimer's, and other devastating conditions have been left waiting for therapies that can address the root cause of their illness, not just the symptoms. The history of CNS drug development is littered with promising candidates that failed because they could not overcome this fundamental delivery challenge.
Our Mission
To halt the progression of devastating neurodegenerative diseases by engineering a new class of intelligent, brain-penetrant biologics.
The Solution, Designed from First Principles
Aetherion is overcoming the blood-brain barrier challenge with our proprietary Cognate-AI™ Platform.
This is not an incremental improvement on existing technology; it is a complete reimagining of how biologics for the brain are created. Unlike conventional methods that treat delivery and therapy as separate problems—often by "bolting on" a generic transport shuttle to an existing drug—our generative AI platform designs a single, cohesive biologic with co-optimized properties for both brain transport and therapeutic action.
By learning the complex, multi-dimensional rules of protein language, structure, and function, Cognate-AI™ builds the ideal medicine from the ground up, with atomic-level precision.
This is not drug discovery; this is AI-native drug design.
Brain-First Design
Co-optimizes therapeutic action and BBB transport from the molecular level up
Generative AI Engine
Learns protein language, structure, and function to generate novel biologics
Atomic Precision
Designs molecules with unprecedented accuracy and therapeutic potential
The Cognate-AI™ Advantage
Conventional Approach
Separate drug and delivery systems with poor integration
Cognate-AI™
Unified biologic with co-optimized properties
Our Pipeline: From Algorithm to Asset
Advancing Our Lead Program for Parkinson's Disease
AET-101
First-in-Class Bispecific Antibody
Targeting Parkinson's Disease
The power of the Cognate-AI™ platform is demonstrated by the rapid advancement of our pipeline. Our discovery engine has generated AET-101, a first-in-class bispecific antibody engineered to neutralize pathogenic alpha-synuclein, a primary driver of neurodegeneration in Parkinson's Disease.
By designing AET-101 for efficient BBB transport and potent target engagement from the outset, we have created a promising therapeutic candidate that is currently advancing through IND-enabling studies.
Platform Productivity
Leading AI-driven biotechnology companies understand that a platform's credibility is ultimately measured by its productivity.
Months from target to lead candidate
Reduction in traditional screening time
Programs in active development